Abstract
1 min readBGM Durie, J-L Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and SV Rajkumar on behalf of the International Myeloma Working Group Aptium Oncology, Inc., Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA; Institute de Biologie, Nantes, France; University of Salamanca, Salamanca, Spain; Hospital Clinica, Barcelona, Spain; MIRT UAMS, Little Rock, Arkansas, USA; DFCI, Boston, MA, USA; Mayo Clinic, Rochester, MN, USA; Alexandra Hospital, Athens, Greece; University of Gothenberg, Gothenberg, Sweden; Rotterdam, The Netherlands; Wilhelminenspital Der Stat Wien, Vienna, Austria; Karolinska Institutet, Stockholm, Sweden; Ankara University, Turkey; Cancer Research and Biostatistics, Seattle, WA, USA; Cross Cancer Institute, Canada; University of Torino, Torino, Italy; University of Malmo, Malmo, Sweden; Royal Prince Alfred Hospital, Sydney, Australia; St Vincent’s Comprehensive Cancer Center, New York, NY, USA; MD Anderson, Houston, TX, USA; Purpan Hospital, Toulouse, France; University of Pavia, Pavia, Italy; The Leukemia and Myeloma Program, Wimbledon, UK; Dana Farber Cancer Institute, Boston, MA, USA; Nagoya City Midori General Hospital, Nagoya, Japan; University of Bologna, Bologna, Italy and Royal Marsden Hospital, London, UK
Discussion(0)
No comments yet. Be the first to comment.